Table 3.
Effect estimates per unit increase in adipokines or CRP on overall and oestrogen receptor‐stratified breast cancer risk
| Risk factor | Overall breast cancer | ER+ breast cancer | ER− breast cancer | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | p‐Value | OR (95% CI) | p‐Value | OR (95% CI) | p‐Value | |
| Adiponectin | 1.06 (0.81–1.40) | 0.66 | 0.98 (0.71–1.35) | 0.91 | 1.19 (0.92–1.54) | 0.18 |
| CRP | 1.03 (0.94–1.13) | 0.48 | 1.04 (0.95–1.14) | 0.40 | 1.05 (0.93–1.19) | 0.41 |
| HGF | 1.01 (0.93–1.10) | 0.77 | 1.01 (0.92–1.11) | 0.86 | 1.17 (1.01–1.35) | 0.035 |
| IL‐6 | 1.09 (0.96–1.25) | 0.18 | 1.12 (0.96–1.31) | 0.14 | 1.00 (0.79–1.27) | 0.99 |
| Leptin receptor | 1.00 (0.99–1.01) | 0.63 | 1.00 (0.99–1.01) | 0.81 | 1.00 (0.98–1.02) | 0.78 |
| PAI‐1 | 1.03 (0.80–1.33) | 0.83 | 0.98 (0.78–1.24) | 0.87 | 1.05 (0.65–1.68) | 0.85 |
| Resistin | 0.98 (0.91–1.04) | 0.48 | 0.98 (0.91–1.06) | 0.61 | 0.99 (0.87–1.11) | 0.81 |
Abbreviations: CI, confidence interval; CRP, C‐reactive protein; ER+, oestrogen receptor positive; ER−, oestrogen receptor negative; HGF, hepatocyte growth factor; IL‐6, interleukin‐6; OR, odds ratio; PAI‐1, plasminogen activator inhibitor‐1.
Effect estimates represent the effect of a one unit increase in: natural log‐transformed adiponectin, CRP, IL‐6 and PAI‐1 and standardised HGF, leptin receptor and resistin.